Product
Oral Topotecan + Anlotinib
1 clinical trial
1 indication
Indication
Platinum-resistant Ovarian CancerClinical trial
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer：Status: Withdrawn, Estimated PCD: 2026-02-01